Dignify Therapeutics, LLC
Dignify Therapeutics is dedicated to restoring control of bowel and bladder functions for individuals with neurological conditions. Their mission is to develop safe, effective, practical, and convenient 'on-demand' pharmaceutical agents to treat bladder and bowel voiding dysfunctions, addressing significant unmet medical needs in a multi-billion dollar market.
Industries
Nr. of Employees
small (1-50)
Dignify Therapeutics, LLC
P.O. Box 13169, 2 Davis Drive, Research Triangle Park, NC 27709
Patents
Products
Rectal suppository candidate for on‑demand bowel evacuation (lead candidate)
A suppository formulation intended to induce defecation within approximately 5–10 minutes with minimal systemic absorption and exposure; developed as an on‑demand bowel evacuation therapy for patients with neurogenic and other bowel dysfunctions.
Rapid‑acting peptide candidate for bladder and bowel voiding (lead candidate)
A small peptide therapeutic designed to directly stimulate smooth muscle contraction in bladder and bowel, producing voiding in under ~10 minutes and optimized for short systemic half‑life and rapid elimination.
Rectal suppository candidate for on‑demand bowel evacuation (lead candidate)
A suppository formulation intended to induce defecation within approximately 5–10 minutes with minimal systemic absorption and exposure; developed as an on‑demand bowel evacuation therapy for patients with neurogenic and other bowel dysfunctions.
Rapid‑acting peptide candidate for bladder and bowel voiding (lead candidate)
A small peptide therapeutic designed to directly stimulate smooth muscle contraction in bladder and bowel, producing voiding in under ~10 minutes and optimized for short systemic half‑life and rapid elimination.
Services
Negotiation and execution of licensing agreements and collaboration deals for therapeutic candidates; engagement with investors and industry partners.
Collaborative preclinical testing partnerships to perform urodynamics and in vivo pharmacology studies supporting lead candidate progression.
Preparation of clinical development plans and presentation of program status to investors and industry stakeholders at conferences and forums.
Negotiation and execution of licensing agreements and collaboration deals for therapeutic candidates; engagement with investors and industry partners.
Collaborative preclinical testing partnerships to perform urodynamics and in vivo pharmacology studies supporting lead candidate progression.
Preparation of clinical development plans and presentation of program status to investors and industry stakeholders at conferences and forums.
Expertise Areas
- Translational drug development for neurogenic bladder and bowel disorders
- Peptide therapeutic design and formulation for localized delivery
- Preclinical pharmacology and urodynamics testing
- Early‑phase clinical development planning
Key Technologies
- Peptide therapeutics
- Rectal suppository/local delivery formulations
- Preclinical urodynamics assays
- In vivo pharmacology models of neurogenic bladder/bowel
News & Updates
Dignify Therapeutics announced their participation in the BIO Partnering at JPM Week event scheduled from January 8 to January 12, 2024, in San Francisco, CA.
Dignify Therapeutics participated in the CED Venture Connect event on March 20-21, 2024, in March 2024.
Dignify Therapeutics scheduled to participate in the BIO International Convention 2025 from June 15 to June 18, 2025, in Boston, MA.
Dignify Therapeutics participated in the BIO CEO & Investor Conference on February 10-11, 2025, in New York, NY.
Dignify Therapeutics participated in the American Spinal Injury Association Annual Scientific Meeting from June 2 to June 4, 2025, in Scottsdale, AZ.
Dignify Therapeutics participated in the BIO Investor Forum on October 15-16, 2024, in San Francisco, CA.
Dignify Therapeutics announced their participation in the BIO Partnering at JPM Week event scheduled from January 8 to January 12, 2024, in San Francisco, CA.
Dignify Therapeutics participated in the CED Venture Connect event on March 20-21, 2024, in March 2024.
Dignify Therapeutics scheduled to participate in the BIO International Convention 2025 from June 15 to June 18, 2025, in Boston, MA.
Dignify Therapeutics participated in the BIO CEO & Investor Conference on February 10-11, 2025, in New York, NY.
Dignify Therapeutics participated in the American Spinal Injury Association Annual Scientific Meeting from June 2 to June 4, 2025, in Scottsdale, AZ.
Dignify Therapeutics participated in the BIO Investor Forum on October 15-16, 2024, in San Francisco, CA.